Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.
Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.
Active, not recruiting · NCT07654530 · Registry updated 2026-06-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC. | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-06-17 | NCT07654530 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tianjin Medical University Cancer Institute and Hospital | 287 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tianjin Medical University Cancer Institute and Hospital | Tianjin | China | 66 |